Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from D.Western Therapeutics Institute ( (JP:4576) ).
D.Western Therapeutics Institute, in collaboration with RaQualia Pharma, has achieved positive results in their joint research aimed at developing new drug candidates for eye diseases. This research, which began in December 2022, confirmed favorable pharmacological effects in animal models and is expected to contribute to the medium-to-long-term expansion of DWTI’s ophthalmology pipeline, though it will not impact the current fiscal year’s earnings forecast.
More about D.Western Therapeutics Institute
D.Western Therapeutics Institute is a biotech company focused on developing innovative new drugs, particularly in the ophthalmic field. They specialize in kinase inhibitors and have proprietary drugs on the market, with a mission to deliver effective medicines quickly to patients.
Average Trading Volume: 2,903,641
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen4.62B
See more insights into 4576 stock on TipRanks’ Stock Analysis page.